Effects of teriparatide retreatment in osteoporotic men and women

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 7, 2009, Pages 2495-2501

  Finkelstein, Joel S ^a   Wyland, Jason J ^a   Leder, Benjamin Z ^a   Burnett Bowie, Sherri Ann M ^a   Lee, Hang ^a   Jüppner, Harald ^a   Neer, Robert M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIUM; COLLAGEN TYPE 1; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; SPINAL CORD; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; VITAMIN SUPPLEMENTATION;

EID: 67650254286     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0154     Document Type: Article

References (31)

1. Finkelstein JS 2000 Osteoporosis. In: Goldman L, Bennett JC, eds. Cecil textbook of medicine. 21st ed. Philadelphia: W.B. Saunders Company; 1366-1373
2. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618-1623
3. Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM 1998 Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized, controlled trial. JAMA 280:1067-1073
4. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
5. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
6. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
7. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076
8. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17
9. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB 2002 A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528-4535
10. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970
11. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R 2005 Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566-575
12. Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751
13. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM 2006 Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 91:2882-2887
14. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM 1993 An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 91:1138-1148
15. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555
16. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768
17. Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR 1993 The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:1577-1584
18. Liu CC, Kalu DN, Salerno E, Echon R, Hollis BW, Ray M 1991 Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J Bone Miner Res 6:1071-1080
19. Mitlak BH, Williams DC, Bryant HU, Paul DC, Neer RM 1992 Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats. J Bone Miner Res 7:479-484
20. Wronski TJ, Yen CF, Qi H, Dann LM 1993 Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 132:823-831
21. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555-565
22. Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA 2006 Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 21:283-291
23. Young G, Marcus R, Minkoff JR, Kim LY, Segre GV 1987 Age-related rise in parathyroid hormone in man: the use of intact and midmolecule antisera to distinguish hormone secretion from retention. J Bone Miner Res 2:367-374
24. Taylor A, Konrad PT, Norman ME, Harcke HT 1997 Total body bone mineral density in young children: influence of head bone mineral density. J Bone Miner Res 12:652-655
25. Hesch RD, Heck J, Delling G, Keck E, Reeve J, Canzler H, Schober O, Harms H, Rittinghaus EF 1988 Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38) hPTH and diphosphonate EHDP. Klin Wochenschr 66:976-984
26. Hodsman AB, Fraher LJ 1990 Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. Bone Miner 9:137-152
27. Mitlak BH, Burdette-Miller P, Schoenfeld D, Neer RM 1996 Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat. J Bone Miner Res 11:430-439
28. Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH 16 October 2008 Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 10.1007/s00198-008-0766-0
29. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
30. Finkelstein JS, Arnold AL 1999 Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab 84:1214-1219
31. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129-2134